by Medina LJ, Chassaing E, Ballering G, Gonzalez N, Marqué L, Liehl P, Pottel H, de Boer J, Chatelain E, Zrein M, Altcheh J. The Lancet Infectious Diseases 2021, 21(8): 1141-50. doi: 10.1016/S1473-3099(20)30729-5
Summary: Parasitological cure of patients with chronic Chagas disease is currently assessed by conversion from positive to negative Trypanosoma cruzi serology (seroreversion), but this can take years to decades. This study evaluated the MultiCruzi assay as a predictive tool for parasitological cure in a cohort of treated infants and children with acute and chronic Chagas disease enrolled in a long-term retrospective longitudinal study. Combining experimental data from discrete analysis of 15 T. cruzi antigens efficiently predicted seroreversion at an early stage, which was later confirmed by conventional T. cruzi serology. The MultiCruzi assay can be used as a predictive monitoring tool to assess parasitological cure in children and might enable forecasting of forthcoming seroreversion in treated adults infected with T. cruzi.
